
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech has demonstrated robust growth, with surgical soft tissue repair product sales rising 24% year-over-year to $23.4 million, largely driven by increased demand for its CellerateRX Surgical Activated Collagen. The company's revenue from soft tissue repair products increased by 28% year-over-year, highlighting its strong market position and potential for continued expansion. Additionally, the strategic initiatives aimed at broadening distribution networks and entering new healthcare facilities are expected to support sustained revenue growth, positioning the company for profitability in the coming quarters.
Bears say
Sanara MedTech Inc. reported net revenue of $26.3 million, reflecting a year-over-year growth of 21.5%, though this figure fell short of projections. The company faces multiple risks, including lower-than-anticipated revenue growth, challenges in acquiring additional customers, and difficulties in launching new products or services. Furthermore, a reduction in the enterprise value to revenue multiple from 4.3x to 3.0x indicates a decline in market confidence, particularly following the discontinuation of its telehealth segment.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares